Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors

Germ cell tumors (GCTs) represent a heterogeneous neoplasm family affecting gonads and rarely occurring in extragonadal areas. Most of patients have a good prognosis, often even in the presence of metastatic disease; however, in almost 15% of cases, tumor relapse and platinum resistance are the main...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2023-02, Vol.14, p.1118610-1118610
Main Authors: Schepisi, Giuseppe, Gianni, Caterina, Cursano, Maria Concetta, Gallà, Valentina, Menna, Cecilia, Casadei, Chiara, Bleve, Sara, Lolli, Cristian, Martinelli, Giovanni, Rosti, Giovanni, De Giorgi, Ugo
Format: Article
Language:English
Subjects:
CAR-T
Cell- and Tissue-Based Therapy
chimeric antigen receptor
GCT
germ cell tumors
Humans
Immune Checkpoint Inhibitors
Immunology
Neoplasms, Germ Cell and Embryonal - therapy
Platinum
Receptors, Chimeric Antigen - genetics
testicular cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Germ cell tumors (GCTs) represent a heterogeneous neoplasm family affecting gonads and rarely occurring in extragonadal areas. Most of patients have a good prognosis, often even in the presence of metastatic disease; however, in almost 15% of cases, tumor relapse and platinum resistance are the main challenges. Thus, novel treatment strategies with both improved antineoplastic activity and minor treatment-related adverse events compared with platinum are really expected. In this context, the development and the high activity demonstrated by immune checkpoint inhibitors in solid tumors and, subsequently, the interesting results obtained from the use of chimeric antigen receptor (CAR-) T cell therapy in hematological tumors, have stimulated research in this direction also in GCTs. In this article, we will analyze the molecular mechanisms underlying the immune action in the development of GCTs, and we will report the data from the studies that tested the new immunotherapeutic approaches in these neoplasms.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1118610